接受大型腹部手术的维多珠单抗治疗克罗恩病患者的术后结局
本研究回顾性比较了12周内接受维多珠单抗、肿瘤坏死因子α抑制剂或无生物制剂治疗的克罗恩病患者的30天术后感染并发症。维多珠单抗组手术部位感染率显著高于抗肿瘤坏死因子α组和无生物制剂组(26% vs 8%和11%,P<.001),多因素分析显示维多珠单抗暴露仍是术后手术部位感染的显著预测因素。
要点
- 维多珠单抗组30天术后手术部位感染率为26%,显著高于抗肿瘤坏死因子α组的8%和无生物制剂组的11%。
- 多因素分析显示,手术前12周内使用维多珠单抗仍是30天术后手术部位感染的显著预测因素(P=.002)。
- 维多珠单抗组非手术部位感染率与对照组无显著差异(6% vs 5%和2%,P=.34)。
核心结论
- 在接受大型腹部手术前12周内使用维多珠单抗的克罗恩病患者中,26%出现30天术后手术部位感染,显著高于接受肿瘤坏死因子α抑制剂或无生物制剂治疗的患者。
- 多因素分析显示,手术前12周内使用维多珠单抗仍是30天术后手术部位感染的预测因素。
- 作者认为,尽管维多珠单抗治疗的克罗恩病患者可能是病情更重的人群,但考虑这些发现对于术前咨询、手术时机和伤口一期闭合具有重要意义。
研究设计与样本
- 回顾性综述,纳入在大型腹部或盆腔手术前12周内接受维多珠单抗的克罗恩病患者100例。
- 两个对照组分别为接受肿瘤坏死因子α抑制剂治疗的克罗恩病患者和未接受生物制剂治疗的克罗恩病患者。
主要发现
- 维多珠单抗组接受腹腔镜手术的比例与对照组相当(P=.25),吻合口数量更少(P=.0002),在吻合时行转流的频率与对照组相同(P=.47)。
- 维多珠单抗组32例(32%)发生术后感染并发症,其中26例(26%)为手术部位感染。
- 维多珠单抗组非手术部位感染率与抗肿瘤坏死因子α组和无生物制剂组无差异(6% vs 5%和2%,P=.34)。
- 维多珠单抗组手术部位感染率显著高于抗肿瘤坏死因子α组和无生物制剂组(26% vs 8%和11%,P<.001)。
- 单因素和多因素分析显示,维多珠单抗暴露仍是术后手术部位感染的显著预测因素(P<.001和P=.002)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Up to 80% of patients with Crohn's disease require an abdominal operation in their lifetime. As the use of vedolizumab is increasing for the treatment of Crohn's disease, it is important to understand its potential association with post-operative complications. AIM: We sought to compare 30-day postoperative infectious complication rate among vedolizumab-treated Crohn's disease patients vs those who had received TNFα inhibitors or no biologic therapy. METHODS: A retrospective review of all Crohn's disease patients who received vedolizumab within 12 weeks of a major abdominal or pelvic operation was performed. Two control cohorts consisted of Crohn's disease patients treated with TNFα inhibitors or no biologic therapy. RESULTS: One hundred Crohn's disease patients received vedolizumab within 12 weeks of an abdominal operation. Vedolizumab-treated patients underwent an equivalent rate of laparoscopic surgery (P = .25), had fewer anastomoses performed (P = .0002), and had equally frequent diversion in the setting of anastomoses (P = .47). Thirty-two vedolizumab-treated patients experienced postoperative infectious complications (32%), 26 of which were surgical site infections (26%). The vedolizumab-treated group experienced no difference in nonsurgical site infections (6% vs 5% anti-TNFα and 2% nonbiologic; P = .34), but significantly higher rates of surgical site infections (26% vs 8% and 11%; P < .001). On univariate and multivariate analysis, exposure to vedolizumab remained a significant predictor of postoperative surgical site infection (P < .001 and P = .002). CONCLUSIONS: Twenty-six per cent of Crohn's disease patients who received vedolizumab within 12 weeks prior to a major abdominal operation experienced a 30-day postoperative surgical site infection, significantly higher than that of patients receiving TNFα inhibitors or no biologic therapy. Vedolizumab within 12 weeks of surgery remained a predictor of 30-day postoperative surgical site infection on multivariable analysis. While vedolizumab-treated Crohn's disease patients may be a sicker cohort of patients, it is important to consider these findings with regard to preoperative counselling, operative timing and primary closure of wounds.
引用
- Lightner AL, McKenna NP, Tse CS, et al. Postoperative outcomes in vedolizumab-treated Crohn's disease patients undergoing major abdominal operations. Aliment Pharmacol Ther. 2017. PMID: 29250800. doi:10.1111/apt.14459
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。